SOFINNOVA CAPITAL VI FCPR 4
4 · HOOKIPA Pharma Inc. · Filed Apr 25, 2019
Insider Transaction Report
Form 4
SOFINNOVA CAPITAL VI FCPR
10% Owner
Transactions
- Conversion
Common Stock
2019-04-23+888,166→ 3,606,712 total - Conversion
Series B Preferred Stock
2019-04-23−1,719,189→ 0 total→ Common Stock (1,719,189 underlying) - Conversion
Common Stock
2019-04-23+916,901→ 999,357 total - Conversion
Common Stock
2019-04-23+1,719,189→ 2,718,546 total - Conversion
Series A Preferred Stock
2019-04-23−916,901→ 0 total→ Common Stock (916,901 underlying) - Conversion
Series C Preferred Stock
2019-04-23−888,166→ 0 total→ Common Stock (888,166 underlying) - Purchase
Common Stock
2019-04-23$14.00/sh+357,142$4,999,988→ 3,963,854 total
Footnotes (2)
- [F1]The preferred stock automatically converted into the Issuer's common stock on a one-for-one basis at the closing of the Issuer's initial public offering held on April 23, 2019 without payment or further consideration and had no expiration date.
- [F2]Sofinnova Partners SAS is the managing company of Sofinnova Capital VI FCPR and disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.